Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GLP-1 drugs like semaglutide deliver impressive weight loss in teens with obesity, but long-term safety data is virtually nonexistent. A new review presented at the AAP 2026 National Conference found that few trials have measured bone density, lean mass, or neurodevelopment in adolescents. Experts warn that benefits reverse once the medication stops — and families deserve honest conversations about what we still don't know.
GLP-1 medications like semaglutide are delivering real results for teens with obesity — but the science hasn't caught up with the prescriptions yet. A structured review presented at the AAP 2026 National Conference analyzed 30 sources, including three placebo-controlled trials, and found significant BMI reductions in adolescents. The catch? Almost no trials have assessed bone density, lean mass, or neurodevelopment — critical concerns during a period of peak growth.
The weight loss numbers are striking, but so are the caveats. When teens stop taking these medications, the weight comes back — a pattern seen across multiple GLP-1 drugs in both adults and adolescents. Experts stress that these medications should be a tool, not the cornerstone of treatment, and that physical activity, nutrition, and family involvement remain essential.
By the Numbers:
Why it matters: With 1 in 5 US teens living with obesity and weight regain nearly guaranteed after stopping GLP-1 therapy, clinicians need long-term data — especially on bone and lean mass — before these drugs become a default pediatric treatment.
